

## DAFTAR PUSTAKA

- Abenavoli, L., Corpechot, C., Poupon, R. 2007. Elastography in hepatology. *Can. J. Gastroenterology*. 21(12):839-842.
- Abraldes, J.G., Albillos, A., Bañares, R., Turnes, J., González, R., García-Pagán, J.C., *et al.* 2009. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. *Gastroenterol*. 136(5):1651-8.
- Abraldes, J.G., Villanueva, C., Aracil, C., Turnes, J., Hernandez-Guerra, M., Genesca, J., *et al.* 2016. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. *Gastroenterology*. 150:1160–1170.
- Azer, S.A., Katz, J. 2012. Esophageal varices. Available from: URL: <http://emedicine.medscape.com/article/175248-overview>
- Bataller, R., Brenner, D. 2005. Liver fibrosis. *J. Clin. Invest*. 115(4):1100.
- Bays, H., Cohen, D.E., Chalasani, N., dan Harrison, S.A. 2014. An assessment by the statin liver safety task force: 2014 update. *J. Clin. Lipidol*. 8(3 Suppl):S47-57.
- Benedeto-Stojanov, D., Nagorni, A., Bjelaković, G., Stojanov, D., Mladenović, B., Djenić, N. 2009. The model for the end-stage liver disease and Child-Pugh score in predicting prognosis in patients with liver cirrhosis and esophageal variceal bleeding. *Vojnosanit Pregl*. 66(9):724-8.
- Botta, F., Giannini, E., Romagnoli, P., Fasoli, A. 2003. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function. *Gut*. 52:134 - 9.
- Boursier, J., Cesbron, E., Tropet, A., Pilette, C. 2009. Comparison and improvement of MELD and Child-Pugh score accuracies for the prediction of 6 month mortality in cirrhotic patients. *J. Clin. Gastroenterol*. 43:580–585.
- Cahyono, J.B.S.B. 2014. Tatalaksana Klinis Di Bidang Gastro Dan Hepatologi. Hal.:102-106. Sagung Seto, Jakarta.
- Canbay, A., Higuchi, H., Bronk, S.F., Taniai, M., Sebo, T.J., Gores, G.J. 2002. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. *Gastroenterology*. 123: 1323-30.

- Chan, H.L., Chim, A.M., Lau, J.T., Hui, A.Y., Wong, V.W., Sung, J.J. 2006. Evaluation of model for endstage liver disease for prediction of mortality in decompensated chronic hepatitis B. *Am. J. Gastroenterol.* 101:1516–1523.
- Cholongitas, E., Papatheodoridis M., Vangeli, M. 2005. Systematic review: The model for end-stage liver disease - should it replace Child Pugh's classification for assesing prognosis in cirrhosis?. *Aliment Pharmacol. Ther.* 22:1079-1089.
- Cobbold, J.F.L, Morin, S., and Taylor-Robinson, S.D. 2007. Transient elastography for the assesment of chronic liver disease: ready for clinic. *World J. Gastroenterol.* 13(36):4791–4797.
- Cohen-Naftaly, M., Friedman, S.L. 2011. Current status of novel antifibrotic therapies in patients with chronic liver disease. *Therap. Adv. Gastroenterol.* 4(6):391-417.
- D'Amico, G., Garcia-Tsao, G., Pagliaro, L. 2006. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. *J. Hepatol.* 44(1):217-31.
- Dancygier, H. 2010. *Liver cirrhosis in clinical hepatology: Principles and Practice of Hepatobiliary Diaseases: Volume 2.* Springer-Verlag, Berlin.
- Durand, F., Valla, D. 2005. Assesment of the prognosis of cirrhosis: Child Pugh vs MELD. *J. Hepatol.* 42 Suppl 1:100-7.
- Dienstag, J.L., Goldin, R.D., Heathcote, E.J., Hann, H.W., Woessner. M., Stephenson, S.L., *et al.* Histological outcome during long-term lamivudine therapy. *Gastroenterology.* 124(1):105-17.
- Ferri, F. 2015. *Ferri's clinical Advisor 1<sup>st</sup> Edition: Chirrosis.* Elsevier, Philadelphia.
- Flores, P.P., Soldan, M., Rezend, G.F. 2015. Cirrhotic portal hypertension: New insight in an old syndrome. *Revista Saude e Pesquisa.* 8(2):389-97.
- Flores-Rendón, A.R., González-González, J.A., García-Compean, D., Maldonado-Garza, H.J., Garza-Galindo, A.A. 2008. Model for end stage of liver disease (MELD) is better than the Child-Pugh score for predicting in-hospital mortality related to esophageal variceal bleeding. *Annals of Hepatology.* 7(3):230-234
- Foucher, J., Chanteloup, E., Vergniol, J., Castér, L., Le Bail, B., Adhoute, X., *et al.* 2006. Diagnosis of cirrhosis by transient elastography (fibroscan): A prospective study. *Gut.* 55(3):403-8.

- Franchis, R. 2005. Evolving concensus in portal hypertension: Report of the baveno iv consensus workshop on methodology of diagnosis and therapy in portal hypertension. *J. Hepatol.* 43:167-176.
- Friedmann, S.L. 2008. Mechanisms of hepatic fibrogenesis. *J. Gastroenterology.* 134(6):1655–1669.
- Friedmann, S.L. 2003. Liver fibrosis from bench to bedside. *J. Hepatol.* 38 Suppl 1:S38-53.
- Gilman, A., Goodman, L. 2008. *The Farmacological Basis Of Therapeutics eleventh edition.* McGraw-Hill, New York.
- Guyton, A.C., Hall, J. 2007. *Buku ajar fisiologi kedokteran edisi 9.* Penerbit Buku Kedokteran EGC, Jakarta.
- Hadi, S. 2012. *Gastroenterologi.* PT. Alumni, Bandung.
- Imamura, H. 2005. Assesment of hepatic reserve for indication of hepatic resection: Decision tree incorporating indocyanine green test. *J. Hepatobiliary Pancreat. Surg.* 12(1):16-22.
- Kamath, P.S., Wiesner, R.H., Malinchoc, M., Kremers, W., Therneau, T.M. 2001. A model to predict survival in patients with end-stage liver disease. *J. Hepatology.* 33:464-470
- Katzung, B.G. 2010. *Farmakologi Dasar Dan Klinik edisi X.* Penerjemah dan Editor: Bagian Farmakologi Fakultas Kedokteran Universitas Erlangga. Salemba Medika, Jakarta.
- Knopp, R.H., Brugts, J.J., Yetgin, T., Hoeks, S.E., Gotto, A.M., Shepherd, J., *et al.* 2009. The benefits of statins in people established cardiovascular disease but with cardiovascular risk factor: Meta analysis of randomized controlled trial. *BMJ.* 338:b2376.
- Kumar, S., Grace, N.D., Qamar, A.A. 2014. Statin use in patients with cirrhosis: A retrospective cohort study. *Dig. Dis. Sci.* 59:1958–1965.
- Kusumobroto, H.O. 2007. Sirosis hati. Dalam: H.A., Sulaiman, H.N., Akbar, L.A., M.S., Noer (Ed.): *Buku Ajar Ilmu Penyakit Hati edisi pertama,* hal.:335-45. Jaya abadi, Jakarta.
- Malinchoc, M., Kamath, P.S., Gordon, F.D., Peine, C.J, Rank, J., terBorg, P.C. 2000. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. *Hepatology.* 31(4):864-71.
- Malizia, G., D’Amico, G. 2016. Statins in cirrhosis: The magic pill?. *Hepatology.* 63(6): 2047-2049.

- Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I.M., *et al.* 2013. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet*. 381(9865):468-75
- Nurdjanah, S. 2009. Sirosis hati. Dalam: A.W., Sudoyo, B., Setiyohadi, I., Alwi, M., Simadibrata, S., Setiati (Ed.): *Buku ajar ilmu penyakit dalam edisi IV*, hal.:443-6. Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia, Jakarta.
- Pollo-Flores, P., Soldan, M., Santos, U.C., Kunz, D.G., Mattos, D.E., da Silva, A.C., *et al.* 2015. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial. *Dig. Liv. Dis.* 7(47):957-963.
- Price, S., Wilson, L. 1994. *Patofisiologi Konsep Klinis Proses-Proses Penyakit*. EGC, Jakarta.
- Rendón, A.R., González, J.A., Compean, D.C., Maldonado-Garza, H.J., Garza-Galindo, A.A. 2008. Model for end stage of liver disease is better than the Child-Pugh score for predicting in-hospital mortality related to esophageal variceal bleeding. *Ann. Hepatol.* 7(3):230-234.
- Rockey, D.C., Friedman, S.L. 2008. Hepatic fibrosis and cirrhosis. *J. Gastroenterology*. 134(6): 1655–1669.
- Russo, W.M., Jacobson, I.M. 2004. How to use statins in patients with chronic liver disease. *Claveland clinic journal of medicine*. 7(1):58-62.
- Sadowitz, B., Maier, K.G., Gahtan, V. 2010. Basic Science Review: Statin Therapy Part I: Pielotropic Effect Of statin In Cardiovascular Disease. *Vasc. Endovascular Surg.* 44(4):241-51.
- Samada, M., Hernandez, J.C. 2012. Prognostic factors for survival in Patient with Liver Cirrhosis. In: H., Abdeldayem (Ed.): *Liver Transplation-Basic Issues*, pp:125-138. Intech, Rijeka.
- Sastroasmoro, Sudigdo, Ismael, S. 2010. *Dasar-Dasar Metodologi Penelitian Klinis edisi ketiga: Pemilihan Subyek Penelitian dan Desain Penelitian*. Sagung Seto, Jakarta.
- Schomerus, H., Hamster, W. 1998. Neuropsychological aspect of portal systemic encephalopathy. *Metab. Brain. Dis.* 13:361-77.
- Sersté, T., Gustot, T., Rautou, P.E., Francoz, C., Njimi, H., Durand, F., *et al.* 2012. Severe hyponatremia is a better predictor of mortality than MELD-Na in patients with cirrhosis and refractory ascites. *J. Hepatol.* 57(2): 274–280.

- Sherlock, S. 2011. The portal venous system and portal hypertension. In: J.S., Dooley, A.S.F., Lok, A.K., Burroughs, E.J. Heathcote (Eds.): *Disease Of The Liver and Biliary System*, pp:147-180. Blackwell, New Jersey.
- Shirin, H., Sharvit, E., Aeed, H., Gavish, D., Bruck, R. 2013. Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats. *World J. Gastroenterol.* 19(2):241–248.
- Stancu, C., Sima, A. 2001. Statins: Mechanism of action and effects. *J. Cell. Mol. Med.* 4(5):378-387.
- Tamargo, J., Caballero, R., Gómez, R., Núñez, L., Vaquero, L., Delpón, E. 2007. Lipid Lowering Therapy With Statins, a New Approach To Anti Arrhythmic Therapy. *Journal of Pharmacology & Therapeutics.* 114:107–126.
- Tandon, V., Bano, G., Khajuria, V., Parihar, A., Gupta, S. 2004. Pleiotropic effect of statins. *Indian J. Pharmacol.* 37:77-85.
- Tsochatzis, E.A., Bosch, J., Burroughs, A.K. 2014. Liver cirrhosis. *The Lancet.* 383: 1749-61.
- Wang, J., Wang, A.J., Li, B.M., Liu, Z.J., Chen, L., Wang, H., *et al.* 2013. MELD-Na: Effective in Predicting Rebleeding in Cirrhosis After Cessation of Esophageal Variceal Hemorrhage by Endoscopic Therapy. *J. Clin. Gastroenterol.* 48(10):870-877
- Wolf, D.C. 2012. Cirrhosis. Available from: URL: <http://emedicine.medscape.com/article/185856overview>
- Wiesner, R., Edwards, E., Freeman, R., Harper, A., Kim, R., Kamath, P., *et al.* 2003. Model for end-stage liver disease (MELD) and allocation of donor livers. *Gastroenterology.* 124(1):91–96.
- Yáñez, M.R., Agulla, J., González, R.R., Sobrino, T., Castillo, J. 2008. Review: Statins and stroke: Therapeutic advanced in cardiovascular disease. *Sage Journal.* 2(3):157-166.
- Yu, I.I., Abola, L. 2006. Predicting prognosis among cirrhotic patients: Child-Pugh versus Apache III versus MELD scoring systems. *Phil. J. Gastroenterol.* 2: 19-24.
- Zafra, C., Abrales, J.G., Turnes, J., Berzigotti, A., Fernández, M., Garca-Pagán, J.C., *et al.* 2004. Simvastatin Enhances Hepatic Nitric Oxide Production and Decrease The Hepatic Vascular Tone In Patients With Cirrhosis. *J. Gastroenterology.* 126(3): 749-55.